Enovis (NYSE:ENOV) Stock Rating Lowered by Wall Street Zen

Enovis (NYSE:ENOV) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other equities research analysts have also recently weighed in on ENOV. UBS Group restated a “buy” rating and set a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. Evercore reiterated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. BTIG Research boosted their price target on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Canaccord Genuity Group dropped their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Finally, Wells Fargo & Company raised Enovis to a “strong-buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $47.43.

Enovis Stock Down 3.7%

NYSE:ENOV opened at $21.74 on Friday. The stock has a 50-day moving average price of $23.26 and a two-hundred day moving average price of $27.52. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -1.05 and a beta of 1.46. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. Enovis has a 1 year low of $21.00 and a 1 year high of $40.69.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The company had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts expect that Enovis will post 2.79 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Oliver Engert bought 1,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the purchase, the insider owned 43,640 shares in the company, valued at $1,112,820. This represents a 2.35% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders have purchased a total of 5,000 shares of company stock valued at $121,983 in the last quarter. Company insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Enovis

Hedge funds have recently modified their holdings of the company. River Road Asset Management LLC grew its position in Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after acquiring an additional 46,289 shares during the last quarter. Corient Private Wealth LLC raised its position in Enovis by 540.7% in the fourth quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock valued at $1,470,000 after purchasing an additional 46,568 shares during the last quarter. Front Street Capital Management Inc. raised its position in Enovis by 75.8% in the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock valued at $9,642,000 after purchasing an additional 156,069 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Enovis during the fourth quarter valued at about $561,000. Finally, Susquehanna Portfolio Strategies LLC boosted its stake in shares of Enovis by 249.9% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock valued at $3,756,000 after purchasing an additional 100,704 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.